Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
5.21
+0.01 (0.19%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Astria Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Astria Therapeutics stock have an average target of 26.6, with a low estimate of 16 and a high estimate of 35. The average target predicts an increase of 410.56% from the current stock price of 5.21.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2025.
Analyst Ratings
The average analyst rating for Astria Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $27 → $28 | Buy | Maintains | $27 → $28 | +437.43% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +207.10% | Mar 11, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $26 | Buy | Reiterates | $26 | +399.04% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +207.10% | Feb 27, 2025 |
| JMP Securities | JMP Securities | Buy Initiates $26 | Buy | Initiates | $26 | +399.04% | Jan 31, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.28M
EPS This Year
-1.96
from -1.68
EPS Next Year
-2.17
from -1.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 5.3M | 15.6M | ||
| Avg | n/a | 1.3M | 3.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,127.1% | ||
| Avg | - | - | 198.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.77 | -1.87 | -1.90 | ||
| Avg | -1.96 | -2.17 | -2.19 | ||
| Low | -2.19 | -2.64 | -2.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.